Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:GRCE NASDAQ:INMB NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.83+4.3%$0.85$0.55▼$2.22$9.83M1.51122,195 shs124,252 shsGRCEGrace Therapeutics$2.39+5.8%$2.63$1.79▼$5.18$36.78M0.37262,541 shs394,925 shsINMBINmune Bio$1.42-0.7%$1.39$1.09▼$11.64$38.02M1.03287,645 shs418,225 shsPYRGFPyroGenesis Canada$0.15-1.0%$0.25$0.12▼$0.53$33.89M0.1960,067 shs53,431 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+10.99%+13.60%-16.46%+17.81%-51.46%GRCEGrace Therapeutics-5.04%+2.26%+2.73%-49.10%-24.67%INMBINmune Bio-1.38%+11.72%-1.38%+21.19%-77.59%PYRGFPyroGenesis Canada-7.33%-9.32%-25.81%-66.89%-56.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.83+4.3%$0.85$0.55▼$2.22$9.83M1.51122,195 shs124,252 shsGRCEGrace Therapeutics$2.39+5.8%$2.63$1.79▼$5.18$36.78M0.37262,541 shs394,925 shsINMBINmune Bio$1.42-0.7%$1.39$1.09▼$11.64$38.02M1.03287,645 shs418,225 shsPYRGFPyroGenesis Canada$0.15-1.0%$0.25$0.12▼$0.53$33.89M0.1960,067 shs53,431 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+10.99%+13.60%-16.46%+17.81%-51.46%GRCEGrace Therapeutics-5.04%+2.26%+2.73%-49.10%-24.67%INMBINmune Bio-1.38%+11.72%-1.38%+21.19%-77.59%PYRGFPyroGenesis Canada-7.33%-9.32%-25.81%-66.89%-56.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07391.14% UpsideGRCEGrace Therapeutics 2.00Hold$6.00151.05% UpsideINMBINmune Bio 2.17Hold$8.00463.38% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APRE, PYRGF, GRCE, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026INMBINmune Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/31/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.003/31/2026APREAprea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $1.20(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K35.35N/AN/A$1.52 per share0.54GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AINMBINmune Bio$50K754.87N/AN/A$0.88 per share1.61PYRGFPyroGenesis Canada$9.14M3.71N/AN/A($0.01) per share-15.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)GRCEGrace Therapeutics-$7.79M-$0.48N/AN/AN/AN/A-14.45%-13.58%8/11/2026 (Estimated)INMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.04N/AN/AN/A-115.14%N/A-60.81%N/ALatest APRE, PYRGF, GRCE, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/18/2026Q4 2026GRCEGrace Therapeutics-$0.24-$0.07+$0.17-$0.06$0.90 millionN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/A3/30/2026Q4 2025INMBINmune Bio-$0.27-$0.18+$0.09-$0.18($0.01) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92GRCEGrace TherapeuticsN/A8.1014.96INMBINmune BioN/A4.244.24PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%GRCEGrace Therapeutics6.08%INMBINmune Bio12.72%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%GRCEGrace Therapeutics11.10%INMBINmune Bio21.40%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataGRCEGrace TherapeuticsN/A16.27 million13.76 millionN/AINMBINmune Bio1026.58 million20.90 millionOptionablePYRGFPyroGenesis Canada90225.46 million96.34 millionNo DataAPRE, PYRGF, GRCE, and INMB HeadlinesRecent News About These CompaniesPyroGenesis Reports Voting Results From 2026 Meeting of ShareholdersJune 23 at 5:04 PM | globenewswire.comPyroGenesis Delivers New Technology to Convert Contaminated Biomass to SyngasJune 17, 2026 | globenewswire.comP. Peter Pascali Updates Early Warning ReportJune 8, 2026 | globenewswire.comPyroGenesis Announces Closing of $2 Million Private PlacementJune 4, 2026 | globenewswire.comPyroGenesis Announces Closing of $6.26 Million in FinancingsJune 3, 2026 | globenewswire.comPyroGenesis Announces Upsize of Bought Deal LIFE Offering to $3.7 MillionMay 20, 2026 | globenewswire.comPyroGenesis Announces $3.0 Million Bought Deal LIFE Offering and Concurrent CEO Private Placement of up to $2.0 MillionMay 19, 2026 | newsfilecorp.comNPyroGenesis Announces a Binding Signed Contract to Acquire its Turcot Manufacturing FacilityMay 14, 2026 | globenewswire.comPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% ...May 7, 2026 | caledonianrecord.comCPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% Year-Over-Year for Best Quarter Since 2022May 7, 2026 | globenewswire.comPyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference CallMay 1, 2026 | globenewswire.comPyroGenesis Provides Corporate Update on NexGen™ Titanium Metal Powder StrategyApril 29, 2026 | globenewswire.comPyroGenesis Announces Appointment of Jean Mayer as Vice-President, Legal Affairs and Corporate SecretaryApril 28, 2026 | globenewswire.comPyroGenesis Produces Battery-Grade Graphite from Carbon Black Using Proprietary Plasma SystemApril 23, 2026 | globenewswire.comPyroGenesis Announces Fourth Quarter and Full Year 2025 ResultsMarch 30, 2026 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private PlacementMarch 26, 2026 | globenewswire.comPyroGenesis Schedules 2025 Fiscal Year Financial Results and Business Update Conference CallMarch 23, 2026 | globenewswire.comPyroGenesis Announces Oversubscription of Non-Brokered Private PlacementMarch 11, 2026 | globenewswire.comPyroGenesis Announces $1 Million Non-Brokered Private PlacementMarch 9, 2026 | globenewswire.comPyroGenesis Confirms Successful Primary Test Campaign with Leading Battery RecyclerMarch 6, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPRE, PYRGF, GRCE, and INMB Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.83 +0.03 (+4.33%) Closing price 04:00 PM EasternExtended Trading$0.83 +0.00 (+0.36%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Grace Therapeutics NASDAQ:GRCE$2.39 +0.13 (+5.75%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.01 (+0.29%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.INmune Bio NASDAQ:INMB$1.42 -0.01 (-0.70%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.02 (-1.41%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.PyroGenesis Canada NASDAQ:PYRGF$0.15 0.00 (-0.99%) As of 03:44 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
